Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Sino Biological lançou recentemente um painel de reagentes de pesquisa para a variante do Ômicron da SARS-CoV-2

  • Latin America - español
  • USA - español
  • USA - English
  • India - English
  • USA - Deutsch
  • USA - Français

News provided by

Sino Biological, Inc.

Dec 07, 2021, 23:33 ET

Share this article

Share toX

Share this article

Share toX

PEQUIM, China, 7 de dezembro de 2021 /PRNewswire/ -- A Sino Biological, Inc. (http://www.sinobiological.com; SHE: 301047) anunciou hoje que lançou um painel de reagentes de pesquisa para a recém-identificada variante Ômicron (B.1.1.529) do vírus SARS-COV-2, que rapidamente levantou preocupações em todo o mundo devido ao alto número de mutações que ela carrega, especialmente as mais de 30 mutações na proteína Spike.

Continue Reading
A Sino Biological lançou recentemente um painel de reagentes de pesquisa para a variante Ômicron da SARS-CoV-2 (B.1.1.529), incluindo proteínas Spike recombinantes de Ômicron (RBD, S1 e S-ECD trimer), anticorpos monoclonais que reconhecem a proteína Spike de Ômicron e o ensaio CRO do pseudovírus Ômicron. (PRNewsfoto/Sino Biological, Inc.)
A Sino Biological lançou recentemente um painel de reagentes de pesquisa para a variante Ômicron da SARS-CoV-2 (B.1.1.529), incluindo proteínas Spike recombinantes de Ômicron (RBD, S1 e S-ECD trimer), anticorpos monoclonais que reconhecem a proteína Spike de Ômicron e o ensaio CRO do pseudovírus Ômicron. (PRNewsfoto/Sino Biological, Inc.)

A nova linha de produtos Ômicron da Sino Biological inclui proteínas Spike recombinantes de Ômicron (RBD, S1 e S-ECD trimer), anticorpos monoclonais que reconhecem a proteína Spike de Ômicron e o ensaio CRO do pseudovírus Ômicron. Esses reagentes são ferramentas de pesquisa críticas e urgentemente necessárias para que cientistas e pesquisadores em todo o mundo entendam o impacto das novas mutações de Ômicron na transmissão viral, bem como anticorpo neutralizante terapêutico e eficácia da vacina profilática.

"A Sino Biological produziu os principais reagentes da proteína spike em um recorde de 11 dias em janeiro de 2020 e apoiou milhares de cientistas e pesquisadores em mais de 70 países em todo o mundo para sua pesquisa sobre a COVID-19, o que resultou em cerca de 1.000 publicações até o momento", disse o CEO da Sino Biological Jie Zhang: "Com a tecnologia de plataforma de última geração e a experiência acumulada ao longo de uma década, em uma corrida contra o tempo e a pandemia, estamos muito satisfeitos em poder produzir a proteína   RBD Ômicron em um novo recorde de seis dias, o anticorpo de ligação spike em oito dias, o spike-S1, as proteínas S-ECD trimer o pseudovírus em dez dias. Continuaremos monitorando novas mutações e nos certificaremos de disponibilizar ferramentas de pesquisa para os cientistas o mais rápido possível."

A Sino Biological fabrica uma lista abrangente de reagentes de pesquisa para apoiar a luta global contra a pandemia da COVID-19 com mais de 400 proteínas e reagentes de anticorpos . Os produtos de proteína e anticorpos da Sino Biological também foram usados para a fabricação de testes de diagnóstico da COVID.

Sobre a Sino Biological

A Sino Biological é uma fornecedora internacional de reagentes biológicos e serviços. A empresa é especializada em produção de antígeno recombinante e desenvolvimento de anticorpos. O portfólio cada vez maior de produtos da empresa inclui mais de 6.000 proteínas recombinantes, 13.000 anticorpos, kits de ensaio ELISA, clones de expressão, meios de cultura celular e outras ferramentas de biologia molecular. A empresa também oferece uma variedade de serviços personalizados, com foco principalmente na produção recombinante de antígenos e anticorpos. A Sino Biological é dedicada à pesquisa de virologia e doenças infecciosas. Sua recém-lançada  coleçãoProVirTM é o maior banco de antígenos virais do mundo, com mais de 1.000 produtos virais de 350 cepas de vírus.

Declarações prospectivas

Algumas declarações neste documento constituem "declarações prospectivas" de acordo com a Lei de Reforma de Litígios de Títulos Privados. Essas declarações são baseadas nas expectativas atuais da administração e estão sujeitas a incertezas e mudanças nas circunstâncias. Os resultados reais podem diferir materialmente daqueles incluídos nessas declarações devido a uma variedade de fatores, sobre os quais a Biological não tem controle. A Sino Biological não assume a obrigação de atualizar essas declarações prospectivas e não tem a intenção de fazê-lo. Mais informações sobre esses fatores podem ser encontradas nos registros da Sino Biological na Bolsa de Valores de Shenzhen.

Foto -https://mma.prnewswire.com/media/1704288/Sino_Biological_newly_launched_a_panel_research_reagents_SARS_CoV_2_Omicron.jpg

FONTE Sino Biological, Inc.

Related Links

www.sinobiological.com

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Die zellfreie Proteinsynthese von Sino Biological unterstützt die in Nature Communications veröffentlichte Protein-Design-Studie des Tencent AI for Life Sciences Lab

Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) hat bekannt gegeben, dass sein Arbeitsablauf für die Gensynthese und zellfreie...

La synthèse protéique acellulaire de Sino Biological appuie l'étude de conception protéique du Tencent AI for Life Sciences Lab publiée dans Nature Communications

Sino Biological, Inc. (Bourse de Shenzhen : 301047.SZ) a annoncé que son processus de synthèse génétique et d'expression protéique acellulaire a été...

More Releases From This Source

Explore

Pharmaceuticals

Pharmaceuticals

Biotechnology

Biotechnology

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content

About

  • About PR Newswire
  • About Cision
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.